Nivolumab-Induced Isolated Adrenal Insufficiency: A Case Report
Authors:
- Rebecca NerilRNRebecca Neril
- Julie LortonJLJulie Lorton
- Joel ZonszeinJZJoel Zonszein
Open Access
- 1 January 2017
- journal article
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 3 (3) , e210-e212
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patientThe Journal of Dermatology, 2016
- Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical reviewClinical Endocrinology, 2016
- Nivolumab-induced hypophysitis in a patient with advanced malignant melanomaEndocrine Journal, 2016
- Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanomaEuropean Journal of Endocrinology, 2015
- In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human PrimatesCancer Immunology Research, 2014
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 2014
- Endocrine Side Effects Induced by Immune Checkpoint InhibitorsThe Journal of Clinical Endocrinology & Metabolism, 2013
- Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissuesScience China Life Sciences, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary, 2009